51 patents
Page 3 of 3
Utility
Use of oil and water emulsions for increasing B cell responses with modified Vaccinia Ankara virus
18 May 20
The invention relates to compositions, uses, and methods for inducing an immune response against a vaccinia virus.
Cédric Cheminay, Robin Steigerwald, Ariane Volkmann
Filed: 11 Mar 15
Utility
Poxvirus Vectors Encoding Hiv Antigens, and Methods of Use Thereof
6 May 20
Poxvirus vectors encoding a synthetic HIV envelope antigen and other HIV antigens, as well as compositions containing such poxvirus vectors and uses of such poxvirus vectors as vaccines to provide improved immunity against HIV, are provided.
Frank WEGMANN, Johannes Petrus Maria LANGEDIJK, Jerôme Hubertina Henricus Victor CUSTERS, Viki BOCKSTAL, Markus KALLA
Filed: 13 Jun 18
Utility
Mva-bn and AD26.ZEBOV or AD26.FILO Prime-boost Regimen
1 Apr 20
Compositions and methods are described for generating an improved effective immune response against an immunogen in humans.
Benoit Christophe Stephan CALLENDRET, Kerstin LUHN-WEGMANN
Filed: 5 Apr 18
Utility
Recombinant modified vaccinia virus Ankara (MVA) multivalent filovirus immunogenic compositions and methods of use
2 Mar 20
The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses.
Ariane Volkmann, Robin Steigerwald, Hubertus Hochrein, Ulrike Dirmeier, Henning Lauterbach, Jürgen Hausmann Hausmann
Filed: 2 Sep 15
Utility
Compositions and Methods for Enhancing the Stability of Transgenes in Poxviruses
26 Feb 20
Provided herein are recombinant poxviruses that are stable through successive passaging of the recombinant poxviruses.
Markus Kalla, Ryan Rountree, Ulrike Dirmeier
Filed: 27 Sep 17
Utility
Methods and compositions for enhancing immune responses
17 Feb 20
Compositions and methods are described for generating an improved effective immune response against an immunogen in humans.
Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier, Benoit Christophe Stephan Callendret, Macaya Julie Douoguih, Lucy A. Ward
Filed: 2 Sep 15
Utility
Methods and compositions for inducing protective immunity against filovirus infection
17 Feb 20
The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.
Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier, Maria Grazia Pau, Benoit Christophe Stephan Callendret, Lucy A. Ward
Filed: 2 Sep 15
Utility
Methods and Compositions for Inducing Protective Immunity Against Filovirus Infection
5 Feb 20
The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.
Ariane VOLKMANN, Robin STEIGERWALD, Ulrike DIRMEIER, Maria Grazia PAU, Benoit Christophe Stephan CALLENDRET, Lucy A. WARD
Filed: 16 Oct 19
Utility
Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
13 Jan 20
Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses.
Cédric Cheminay, Robin Steigerwald, Paul Chaplin
Filed: 8 Nov 18
Utility
Therapeutic HPV vaccine combinations
30 Dec 19
Vectors, vaccines, vaccine compositions and vaccine combinations for use as therapeutics against HPV18 and/or HPV16 are described.
Evelien M. Bunnik, Jerôme H. H. V. Custers, Gerrit C. Scheper, Selina Khan, Markus Kalla, Katrin Weidner
Filed: 30 Apr 17
Utility
Methods and compositions for intra-nasal immunization with recombinant MVA encoding flagellin
23 Dec 19
Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a flagellin, and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increased T-cell and antibody mediated immune responses specific for the heterologous disease-associated antigen when administered to a subject, e.g. a human subject, and related methods and uses.
Henning Lauterbach, Hubertus Hochrein, Stephanie Sanos
Filed: 24 Sep 15